Showing 6951-6960 of 9299 results for "".
- DocBookMD App Offers Secure Communication, HIPAA Compliancehttps://practicaldermatology.com/news/20120424-docbookmd_app_offers_secure_communication_hipaa_compliance/2459816/Doctors can now send X-rays and lab results back and forth, securely and with full HIPAA compliance via a new application, available for iPhone, iPad, and Android. The DocBookMD app is free for doctors who are members of their state or county medical society. All activity is run through a secure ser
- Amgen, Pfizer Will No Longer Co-Market Enbrelhttps://practicaldermatology.com/news/20120419-amgen_pfizer_will_no_longer_co-market_enbrel/2459819/Amgen and Pfizer will end co-promotion of Enbrel (etanercept) in North America this summer, the companies tell the Wall Street Journal. Amgen will assume full marketing responsibilities in the US, effective July 23.
- Study Shows No Association Between NSAIDs and BCChttps://practicaldermatology.com/news/20120418-study_shows_no_association_between_nsaids_and_bcc/2459821/New data question an association between NSAID use and development of BCC, showing that NSAID use was not associated with subsequent incidence of BCC (HR = 1.04, 95% CI: 0.92–1.16) after adjusting for age, sex and estimated lifetime summer sun exposure among a cohort of 58,213 Caucasian Radiologic T
- Survey Results Address Role of UPF Clothing; Top Sunscreenshttps://practicaldermatology.com/news/20120416-survey_results_address_role_of_upf_clothing_top_sunscreens__results_of_a_survey_conducted_at_the_70th_annual_aad_meeting_reveal_that_an_overwhelming_m/2459823/Results of a survey conducted at the 70th Annual AAD Meeting reveal that an overwhelming majority of dermatologists categorize UPF clothing as a first line of defense in sun protection, followed by sunscreen. Respondents also named their top sunscreen choices. The survey, organized by
- Botox Reaches 10-Year Milestone in Aestheticshttps://practicaldermatology.com/news/20120416-botox_reaches_10-year_milestone_in_aesthetics/2459824/Allergan, Inc. marked the 10-year anniversary of the FDA approval of Botox Cosmetic (onabotulinumtoxinA) to improve the look of moderate to severe frown lines between the eyebrows in patients age 18-65.In the decade since Botox Cos
- Lumenis Unveiling New Laser Capability at ASLMShttps://practicaldermatology.com/news/20120413-lumenis_unveiling_new_laser_capability_at_aslms/2459826/Lumenis will unveil UltraPulse's new SCAAR FX CO2 laser treatment capability at the American Society for Laser Medicine and Surgery (ASLMS) annual meeting in Kissimmee, FL. Using up to 150mJoules per pulse, the high energy impact and precision o
- Warning for Blood Clot Risk Added to Drospirenone OCPshttps://practicaldermatology.com/news/20120411-warning_for_blood_clot_risk_added_to_drospirenone_ocps/2459827/The U.S. Food and Drug Administration (FDA) has completed its review of recent observational (epidemiologic) studies regarding the risk of blood clots in women taking drospirenone-containing birth control pills. Drospirenone is a synthetic version of the female hormone, progesterone, also referred t
- Rosacea Awareness: 16 Million Americans Affected, Stressedhttps://practicaldermatology.com/news/20120402-rosacea_awareness_16_million_americans_affected_stressed/2459829/More than 90 percent of more than 1,200 respondents with rosacea said they suffered some form of physical pain from rosacea, according to a new survey by the National Rosacea Society (NRS). With April designated as Rosacea Awareness Month, the NRS strives to educate the public on the effects of rosa
- Medical Students Not Concerned About Skin Cancershttps://practicaldermatology.com/news/20120326-medical_students_not_concerned_about_skin_cancers/2459831/Medical students understand the causes of skin cancer but may be confused about SPF and sunscreen use, comments in recent focus groups suggest. (Arch Dermatol. 148(3):392-393) Surprisingly, most medical students
- Prostaglandin D2 A Potential New Target for Alopecia Therapyhttps://practicaldermatology.com/news/20120326-prostaglandin_d2_a_potential_new_target_for_alopecia_therapy/2459832/Prostaglandin D2 (PGD2) appears to inhibit hair growth in androgenetic alopecia (AGA) and may be potential target for its treatment, new research suggests (Sci Transl Med. 4(126):126ra34). Researchers show that PG